Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eli lilly nederland b.v. - galcanezumab - disturbi fl-emigranja - analgesics, galcanezumab - emgality huwa indikat għall-profilassi ta ' l-emigranja fl-adulti li jkollhom mill-anqas 4-emigranja jiem kull xahar.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - aġenti antineoplastiċi - poteligeo huwa indikat għall-kura ta ' pazjenti adulti b'mycosis fungoides (mf) jew sézary sindromu (ss) li rċevew ta'l-anqas qabel terapija sistemika.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - limfoma, b-cell - aġenti antineoplastiċi - polivy flimkien ma bendamustine u rituximab huwa indikat għall-kura ta ' pazjenti adulti b'reġgħet tfaċċat/refrattarja b kbira mxerrda-cell lymphoma (dlbcl) li mhumiex kandidati għall-trapjant ta'ċelloli staminali ematopojetiċi. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunosoppressanti - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - majloma multipla - aġenti antineoplastiċi - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - mard tal-Ħażna tal-glukoġen tat-tip ii - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm ltd - ofatumumab - lewkimja, linfokitika, kronika, b-Ċellula - antikorpi monoklonali - ma kienux trattati qabel lewkimja limfoċitika kronika (cll): arzerra flimkien ma 'chlorambucil jew bendamustine huwa indikat għall-kura ta' pazjenti b'cll li ma rċevew terapija minn qabel u li mhumiex eliġibbli għall-fludarabine-terapija bbażata fuq. rkadew cll: arzerra huwa indikat flimkien ma 'fludarabine u cyclophosphamide għat-trattament ta' pazjenti adulti b'all rikadut cll. refrattarji cll: arzerra huwa indikat għall-kura ta cll f'pazjenti li huma refrattarji għal pazjenti b'b-ll u alemtuzumab.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - rituximab - lymphoma, non-hodgkin; microscopic polyangiitis; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis - aġenti antineoplastiċi - rituzena huwa indikat fl-adulti għall-indikazzjonijiet li ġejjin:mhux ta 'hodgkin (nhl)rituzena huwa indikat għall-kura ta' pazjenti mhux trattati qabel ma l-istadju iii-iv limfoma follikulari flimkien mal-kimoterapija. rituzena monoterapija hija indikata għat-trattament ta 'pazjenti b'stadju iii-iv limfoma follikulari li huma kemo reżistenti jew li qegħdin fit-tieni jew aktar episodju ta' rkadar wara kimoterapija. rituzena huwa indikat għall-kura ta 'pazjenti bil-tixrid pożittiv cd20 taċ-ċelluli b kbar mhux ta' hodgkin il-limfoma f'kombinazzjoni ma ' chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) l-kimoterapija. lewkimja limfoċitika kronika (cll)rituzena flimkien ma 'kimoterapija huwa indikat għat-trattament ta' pazjenti li ma kienux trattati qabel u li reġgħet tfaċċat/refrattarja cll. hemm biss informazzjoni limitata disponibbli fuq l-effikaċja u s-sigurtà għall-pazjenti li qabel kienu kkurati b'antikorpi monoklonali inkluż rituzenaor pazjenti refrattarji għal preċedenti rituzena flimkien ma ' kimoterapija. granulomatosi b'polianġite u mikroskopika polyangiitisrituzena, flimkien ma 'glukokortikosterojdi, huwa indikat għall-induzzjoni ta' remissjoni f'pazjenti adulti b'mard sever, attiv granulomatosi b'polianġite (wegener) (fap) u polianġite mikroskopika (mpa).